Shared on04 Aug 25Fair value Increased 7.73%
The upward revision in ResMed’s consensus price target reflects a modest increase in its future P/E multiple amid stable profit margins, resulting in a new fair value estimate of $289.71. What's in the News Repurchased 419,000 shares for $100 million, completing 9,210,000 shares repurchased ($863.38 million) under the long-term buyback program.
Shared on30 Apr 25Fair value Decreased 3.39%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Increased 0.21%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Decreased 1.21%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 2.09%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 0.26%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Decreased 0.55%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.